[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: ::
Back to the articles list Back to browse issues page
Pyroptosis-related gene signatures in ovarian cancer treatment follow-up using MRI
W. Chu , D. Huang
Abstract:   (12 Views)
Background: Ovarian cancer remains a significant challenge due to its heterogeneity and variable treatment response. Pyroptosis, an inflammatory form of programmed cell death, may influence tumor progression and treatment outcomes. Dynamic contrast-enhanced MRI (DCE-MRI) is a promising tool for monitoring treatment response in ovarian cancer. This study investigates pyroptosis-related gene (PRG) signatures and their correlation with MRI findings in ovarian cancer treatment follow-up. Materials and Methods: Differentially expressed PRGs (DE-PRGs) were identified from public datasets (e.g., GEO) and intersected with ovarian cancer gene expression data. Core PRGs were selected using LASSO regression, and their expression was correlated with DCE-MRI parameters (tumor perfusion and vascularity). Acetaminophen was evaluated as a potential therapeutic agent, with treatment effects monitored via MRI. Results: Seven core PRGs (e.g., NLRP3, TNFRSF21) were identified, showing significant correlations with tumor vascularity (r=0.71–0.77, p<0.05). DCE-MRI revealed elevated tumor perfusion (0.92±0.15 mL/min/g vs. 0.56±0.12 mL/min/g in controls, p<0.01), strongly associated with NLRP3 and TNFRSF21 expression. Acetaminophen treatment reduced tumor vascularity by 15% (p < 0.05), as observed via DCE-MRI, suggesting a potential therapeutic role. Conclusion: PRG signatures, particularly NLRP3 and TNFRSF21, are promising biomarkers for monitoring ovarian cancer treatment response. DCE-MRI effectively tracks treatment-induced changes in tumor vascularity, supporting its use in follow-up. Acetaminophen’s therapeutic potential requires further validation. Integrating PRG expression with MRI offers a novel approach to personalize ovarian cancer management.
Keywords: Ovarian neoplasms, pyroptosis, magnetic resonance imaging, gene expression profiling, biomarkers.
Full-Text [PDF 1373 kb]   (3 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Back to the articles list Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 50 queries by YEKTAWEB 4735